Y. Peter Li, Ph.D., MBA

Yishan (Peter) Li, Ph.D., MBA, is a cofounder and executive chairman at BlossomHill Therapeutics. Previously, he cofounded San Diego-based oncology biotech company Turning Point Therapeutics, Inc. (Turning Point), later acquired by Bristol Myers Squibb in August 2022 for $4.1 billion. Dr. Li served as chairman and CEO of Turning Point from its founding in 2013 to 2018 and continued to serve as a director until it completed a successful $191 million IPO in 2019. As chairman and CEO of Turning Point, Dr. Li raised $147 million in four rounds of venture financing from leading biotech investors. Under his leadership, the team at Turning Point built a strong pipeline, including the lead compound repotrectinib (AUGTYRO^®) that was approved for locally advanced or metastatic ROS1+ NSCLC, along with additional clinical programs.

Prior to Turning Point, Dr. Li served as executive vice president at Epitomics, Inc. (acquired by Abcam, plc in March 2012), a leading antibody technology company specializing in rabbit monoclonal antibody development for use as reagents, diagnostics and therapeutics. Prior to Epitomics, Dr. Li was vice president at Kenson Ventures, LLC. He served on the board of directors and was an observer of the board for these companies.

Dr. Li earned his MBA from the Haas School of Business, University of California, Berkeley, his doctorate in biochemistry from Ohio State University, where he was a University Presidential Fellow, and his Bachelor of Science from the University of Science and Technology of China. Dr. Li was a postdoctoral research fellow at the Department of Molecular and Cell Biology, University of California, Berkeley. Dr. Li was an honoree for the Committee of 100 Circle of Excellence Award in Humanity in Science & Technology in 2023.